Latest news about Fischer Medical Ventures
Fischer Medical Q1 Results: Revenue up 250% YoY, profit down
Fischer Medical Ventures
35.35
-0.09(-0.25%)
Company Performance:
View Company Insights1D-0.25%
1M-4.12%
6M-7.61%
1Y-66.24%
5Y0.00%
More news about Fischer Medical Ventures
01Jun 26
Fischer Medical FY26 profit surges, dividend declared
Fischer Medical Ventures Limited reported a consolidated net profit of ₹3,101.94 lakh for FY26, a significant increase from ₹120.79 lakh in the previous year, with revenue rising to ₹30,857.56 lakh. The Board recommended a final dividend of ₹0.05 per equity share and appointed S. Ramanand Aiyer & Co. as internal auditors for FY27.
14May 26
WFNS Innovation & Technology Committee Announces Landmark Collaboration with Time Medical International Ventures, Subsidiary of Fischer Medical Ventures
The WFNS Innovation & Technology Committee announced a landmark collaboration with Time Medical International Ventures (India) Pvt. Ltd., a wholly owned subsidiary of Fischer Medical Ventures Limited, on May 14, 2026. This marks the first time in the Committee's history that it has formally partnered with an industry participant. The collaboration will focus on advanced neurosurgical technologies, medical imaging, and global training initiatives. Both organisations aim to set a new benchmark for ethical, innovation-led partnerships in global neurosurgical care.
09Apr 26
Fischer Medical Ventures Submits SEBI Compliance Certificate for Quarter Ended March 31, 2026
Fischer Medical Ventures Limited filed its quarterly compliance certificate under SEBI Depositories Regulations for Q4 FY26 through Company Secretary Balaji Gandla on April 9, 2026. The certificate, issued by RTA Adroit Corporate Services, confirms proper dematerialization processes and regulatory compliance for securities operations during the quarter ended March 31, 2026.
01Apr 26
Fischer Medical Ventures Files SAST Disclosure Following Rs. 10.53 Crore Warrant Conversion
Fischer Medical Ventures completed conversion of 60 lakh convertible warrants into equity shares at Rs. 23.40 per share, generating Rs. 10.53 crores. The transaction increased promoter Shankar Varadharajan's shareholding from 10.64% to 11.46%, triggering mandatory SEBI SAST regulatory disclosures.
24Mar 26
Fischer Medical Ventures Appoints Balaji Gandla as Company Secretary and Compliance Officer
Fischer Medical Ventures Limited appointed Mr. Balaji Gandla as Company Secretary and Compliance Officer effective March 24, 2026, following board approval. Mr. Gandla, an Associate Member of ICSI with over a decade of experience in corporate governance and regulatory affairs, will also serve as Company Secretary of the company's subsidiary Time Medical International Ventures (India) Private Limited.
12Mar 26
Fischer Medical Ventures Opens Special Window for Physical Share Transfer Re-lodgement
Fischer Medical Ventures Limited has opened a special window from February 05, 2026 to February 04, 2027 for re-lodgement of physical share transfer requests that were previously rejected, returned, or not processed due to document deficiencies. The initiative follows SEBI Circular dated January 30, 2026, and was announced through newspaper advertisements in Financial Express and Vishalandra on March 12, 2026. Shareholders are advised to submit required documents to the company's Registrar and Share Transfer Agent during this 12-month window period.
04Mar 26
Fischer Medical Ventures: Invests 75% In PT Fischer Pariko Medical Ventures Shares
Fischer Medical Ventures has expanded into Southeast Asian markets through its wholly owned subsidiary FMV Global Innovations Pte Limited, which acquired a 75% stake in PT Fischer Pariko Medical Ventures. The Indonesian company, incorporated in October 2024, operates in healthcare equipment wholesale distribution, with the investment requiring no direct cash consideration or regulatory approvals.
06Feb 26
Fischer Medical Ventures Promoter Pledges 30 Lakh Shares to HDFC Bank for Working Capital
Fischer Medical Ventures promoter Shankar Varadharajan pledged 30,00,000 equity shares (4.63% of total share capital) to HDFC Bank on February 5, 2026, as collateral for a ₹40 crores loan. The pledged shares, valued at ₹109.59 crores, provide a security cover ratio of 2.74 times the loan amount. The funds will be used for working capital requirements of the company's wholly owned subsidiary to strengthen group operations.
02Feb 26
Fischer Medical Ventures Reports Strong Q3FY26 Performance with Revenue Growth
Fischer Medical Ventures delivered impressive Q3FY26 consolidated performance with revenue reaching ₹10,109.52 lakhs and achieving net profit of ₹1,923.48 lakhs against previous year's loss. The company also announced key organizational changes including resignation of Company Secretary and Malaysian subsidiary restructuring initiative.
21Jan 26
Fischer Medical Ventures Approves Internal Group Reorganisation of Foreign Subsidiary Shares
Fischer Medical Ventures Limited announced that its Executive Business Committee approved the transfer of shares in foreign subsidiary PellucidCare Health Innovations Pte Ltd (Singapore) to wholly owned subsidiary FlynnCare Health Innovations Private Limited as part of internal group reorganisation. The transfer aims to improve administrative and operational efficiency while maintaining unchanged ultimate ownership, control, and economic interest in the foreign subsidiary, with no material impact on consolidated financials.
02Jan 26
Fischer Medical Ventures Limited Updates Board Committee Composition in Regulatory Filing
Fischer Medical Ventures Limited disclosed updated board committee compositions on January 02, 2026, detailing the structure of Audit, Nomination & Remuneration, and Risk Management committees. The committees comprise independent directors, executive management, and senior officers, with Mr. Khairy Jamaluddin Abu Bakar chairing two committees and Ms. Svetlana Rao Raviwada leading the Risk Management Committee.
28Oct 25
Fischer Medical Ventures Reports Robust Q2 Growth with 46-Fold Increase in Net Profit
Fischer Medical Ventures, a medical technology company, reported a significant financial performance boost in Q2. Net profit surged to 139.00 million rupees from 3.00 million rupees year-over-year, a 46-fold increase. Revenue more than doubled to 863.00 million rupees from 397.00 million rupees. The company also announced board changes, appointing Mr. Chan Sing En as Additional Non-Executive Independent Director and recommending Tan Sri Dato' Dr. Syed Jalaludin as Independent Director, both for five-year terms subject to shareholder approval.
Industry Peers
Deepak Fertilisers & Petrochemicals
Tata Chemicals
Gujarat Narmada Valley Fert & Chem
TANFAC Industries
Gujarat Alkalies & Chemicals
GHCL
Grauer & Weil
Chemplast Sanmar
JG ChemicalsFischer Medical Ventures
1,399.30
(-2.58%)
642.50
(-2.02%)
574.15
(-1.02%)
3,168.00
(+2.09%)
699.65
(-1.02%)
434.70
(-1.53%)
71.70
(+0.53%)
176.21
(-3.54%)
633.40
(-2.75%)
35.35
(-0.25%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
